Spirometry reference values after inhalation of 200 μg of salbutamol;Valores de referencia para la espirometría después de la inhalación de 200 μ g de salbutamol

Archivos de Bronconeumologia

Volumn 43, Issue 10, 2007, Pages 530-534

  Pérez Padilla, Rogelio ^a   Bouscoulet, Luis Torre ^a   Vázquez García, Juan Carlos ^a   Muiño, Adriana ^b   Márquez, María ^b   López, María Victorina ^b   De Oca, María Montes ^c   Tálamo, Carlos ^c   Valdivia, Gonzalo ^d   Pertuze, Julio ^d   Jardim, José ^e   Menezes, Ana María B ^f  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^c HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Bronchodilator response; Chronic obstructive pulmonary disease (COPD); Crosssectional study; Latin America; PLATINO; Reference values; Spirometry

Indexed keywords

SALBUTAMOL;

ADULT; AGED; ANAMNESIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; GROUPS BY SEX; HUMAN; HUMAN EXPERIMENT; MALE; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; REFERENCE VALUE; SPIROMETRY; STANDARD; VITAL CAPACITY;

EID: 37849011400     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(07)60123-2     Document Type: Article

References (15)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
2. GOLD. Workshop report, global strategy for diagnosis, management and prevention of COPD. Disponible en: http://www.goldcopd.com/
3. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948-68.
4. Johannessen A, Lehmann S, Omenaas ER, et al. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med. 2006;173:1316-25.
5. Menezes AM, Victora CG, Pérez-Padilla R. The PLATINO project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. BMC Med Res Methodol. 2004;4:15.
6. Menezes AM, Pérez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875-81.
7. Pérez Padilla J, Valdivia G, Muiño A, et al. Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 o más años de edad. Arch Bronconeumol. 2006;42:317-25.
8. Pérez-Padilla R, Vázquez-García J, Márquez M, et al. The long-term stability of portable spirometers used in a multinational study of COPD prevalence. Respir Care. 2006;51:1167-71.
9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
10. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991;144:1202-18.
11. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-87.
12. StataCorp. Stata Statistical Software: release 9.0. College Station, TX: Stata Corporation; 2005.
13. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107-36.
14. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest. 1998;114:1607-12.
15. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987;42:487-90.